首页 > 市场调查报告书 > 医疗设备

体外诊断生技设备

市场调查报告书

商品编码

1722285

肿瘤分子诊断市场规模、份额、成长分析（按类型、产品、技术、最终用户、地区）- 2025-2032 年产业预测

Oncology Molecular Diagnostics Market Size, Share, and Growth Analysis, By Type (Breast Cancer, Prostate Cancer), By Product, By Technology, By End User, By Region, And Segment Forecast, 2025-2032

出版日期: 2025年05月02日 | 出版商:

SkyQuest | 英文 187 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2023 年全球肿瘤分子诊断市场规模为 24.7 亿美元，预计将从 2024 年的 25.7 亿美元成长到 2032 年的 57.8 亿美元，预测期内（2025-2032 年）的复合年增长率为 11.6%。

由于个人化医疗需求的不断增长和全球癌症发病率的上升，肿瘤分子诊断市场正在经历快速成长。这些诊断在早期肿瘤分析和治疗选择中发挥重要作用，使肿瘤学家能够识别影响癌症进展和治疗结果的基因突变和生物标记。次世代定序、聚合酵素链锁反应和原位杂合反应的进步正在增强这些能力。此外，随着基于更深入的肿瘤生物学见解的标靶治疗不断涌现，向精准肿瘤学的转变凸显了伴随诊断的必要性。然而，高昂的检测成本和取得医疗服务的障碍仍然是挑战，尤其是在中低收入国家。技术创新、支持性医疗政策、对协作的重视以及人工智慧在诊断领域的日益普及预计将进一步加强市场环境。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业市场定位（2024年）
主要市场参与者所采取的策略
近期市场趋势
公司市场占有率分析（2024年）
主要企业简介
- 公司详情
- 产品系列分析
- 公司分部份额分析
- 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

Abbott Laboratories（United States）
F. Hoffmann-La Roche Ltd（Switzerland）
Thermo Fisher Scientific Inc.（United States）
Danaher Corporation（United States）
Veracyte Inc.（United States）
Sysmex Corporation（Japan）
Illumina, Inc.（United States）
bioMerieux SA（France）
Agilent Technologies Inc.（United States）
TBG Diagnostics Limited（Australia）
HTG Molecular Diagnostics Inc.（United States）
QIAGEN（Netherlands）
NeoGenomics Laboratories, Inc.（United States）
Foundation Medicine, Inc.（United States）
Natera, Inc.（United States）
Myriad Genetics, Inc.（United States）
Guardant Health（United States）
Exact Sciences Corporation（United States）
Tempus AI（United States）
Flatiron Health（United States）

结论和建议

简介目录

Product Code: SQMIG35A3002

Global Oncology Molecular Diagnostics Market size was valued at USD 2.47 Billion in 2023 and is poised to grow from USD 2.57 Billion in 2024 to USD 5.78 Billion by 2032, growing at a CAGR of 11.6% during the forecast period (2025-2032).

The oncology molecular diagnostics market is experiencing rapid growth driven by the rising demand for personalized medicine and escalating global cancer prevalence. These diagnostics play a crucial role in early tumor profiling and treatment selection, enabling oncologists to pinpoint genetic mutations and biomarkers that influence cancer progression and therapy response. Technological advancements in next-generation sequencing, polymerase chain reaction, and in situ hybridization enhance these capabilities. Additionally, the shift towards precision oncology emphasizes the need for companion diagnostics, as targeted therapies proliferate based on deeper tumor biology insights. However, high test costs and access barriers, particularly in low- and middle-income countries, pose challenges. An emphasis on innovation, supportive health policies, and collaborations, alongside the growing incorporation of AI in diagnostics, is expected to further strengthen the market landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oncology Molecular Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oncology Molecular Diagnostics Market Segments Analysis

The global Oncology Molecular Diagnostics Market is segmented on the basis of type, product, technology, and region. By type, the market is segmented into breast cancer, prostate cancer, colorectal cancer, cervical cancer, liver cancer, lung cancer, blood cancer, kidney cancer, and other cancer. By product, the market is segmented into instruments, reagents and others. By technology, the market is segmented into PCR, In situ hybridization, INAAT, chips and microarrays, mass spectrometry, sequencing, TMA, and others. By end User, the market segmented into hospitals, diagnostic laboratories, academic & research institutes, and others. By region, the market is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.

Driver of the Global Oncology Molecular Diagnostics Market

The global oncology molecular diagnostics market is primarily driven by the rising incidence of cancer across the globe. As the prevalence of cancer continues to escalate, the demand for precise and swift diagnostic methods becomes increasingly vital for improving survival rates. Molecular diagnostics play a crucial role by analyzing cancer at the genetic level, helping to confirm early diagnoses, identify targeted therapies, and facilitate more accurate monitoring of disease progression. This approach not only enhances patient outcomes but also contributes to reducing overall treatment costs, making it a significant factor influencing the growth of the oncology molecular diagnostics market.

Restraints in the Global Oncology Molecular Diagnostics Market

The Global Oncology Molecular Diagnostics market faces several constraints, primarily due to the high costs associated with molecular diagnostic tests, such as next-generation sequencing (NGS) and companion diagnostics. These tests necessitate sophisticated and costly equipment, specialized expertise, and well-organized laboratory environments, which render them financially inaccessible for numerous patients, particularly in low- and middle-income nations. Additionally, stringent reimbursement policies and elevated out-of-pocket expenses further exacerbate challenges in accessing timely care, hindering prompt diagnosis and treatment of cancer. Collectively, these factors are expected to limit the growth of the market significantly.

Market Trends of the Global Oncology Molecular Diagnostics Market

The Global Oncology Molecular Diagnostics market is witnessing a transformative shift driven by technological advancements, particularly in next-generation sequencing (NGS) and liquid biopsy innovations. These methods facilitate faster, non-invasive cancer detection and monitoring, offering enhanced sensitivity and broader genomic coverage essential for both clinical applications and research initiatives. As healthcare providers increasingly adopt these advanced solutions, the demand for accurate and timely diagnostic tools continues to grow. This trend signifies a pivotal move towards personalized medicine, empowering clinicians with vital data to tailor therapies, ultimately improving patient outcomes and fueling market expansion in the oncology diagnostics landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Matrix
Regulation Matrix

Global Oncology Molecular Diagnostics Market Size by Type & CAGR (2025-2032)

Market Overview
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Lung Cancer
Blood Cancer
Kidney Cancer
Other Cancer

Global Oncology Molecular Diagnostics Market Size by Product & CAGR (2025-2032)

Market Overview
Instruments
Reagents
Others

Global Oncology Molecular Diagnostics Market Size by Technology & CAGR (2025-2032)

Market Overview
PCR
In Situ Hybridization
INAAT
Chips and Microarrays
Mass Spectrometry
Sequencing
TMA
Others

Global Oncology Molecular Diagnostics Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Diagnostic Laboratories
Academic & Research Institutes
Others

Global Oncology Molecular Diagnostics Market Size & CAGR (2025-2032)

North America (Type, Product, Technology, End User)
- US
- Canada
Europe (Type, Product, Technology, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Product, Technology, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Product, Technology, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Product, Technology, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Abbott Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Veracyte Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TBG Diagnostics Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
HTG Molecular Diagnostics Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NeoGenomics Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Foundation Medicine, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tempus AI (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Flatiron Health (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments